- Molecular NameCarbimazole
- SynonymAthyromazole; Carbethoxymethimazole; Carbimazol; Carbimazol [INN-Spanish, French]; Carbimazolum [INN-Latin]; Carbinazole
- Weight186.235
- Drugbank_IDDB00389
- ACS_NO22232-54-8
- Show 3D model
- LogP (experiment)0.842
- LogP (predicted, AB/LogP v2.0)0.24
- pkaN/A
- LogD (pH=7, predicted)0.24
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-1.31
- LogSw (predicted, AB/LogsW2.0)7.9
- Sw (mg/ml) (predicted, ACD/Labs)9.11
- No.of HBond Donors0
- No.of HBond Acceptors4
- No.of Rotatable Bonds2
- TPSA64.87
- StatusFDA approved
- AdministrationN/A
- PharmacologyCarbimazole is a pro-drug as after absorption it is converted to the active form, methimazole. Methimazole prevents the thyroid peroxidase enzyme from coupling and iodinating the tyrosine residues on thyroglobulin, hence reducing the production of the thyroid hormones T3 and T4 (thyroxine).
- Absorption_value95.0
- Absorption (description)Carbimazole is rapidly and almost completely absorbed after oral administration
- Caco_2N/A
- Bioavailability0.0
- Protein binding85.0
- Volume of distribution (VD)Thiamazole, about 0.5 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmConverted to the active metabolite thiamazole.
- Half lifethiamazole about 3 to 5 h
- ExcretionIt is almost completely excreted in the urine in 24 h as metabolites; 3-methyl-2-thiohydantoin has been identified as a minor metabolite in urine and plasma. About 3% of a dose is eliminated in the faeces.
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityN/A
- LD50 (rat)N/A
- LD50 (mouse)N/A